Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis (review)

被引：0
|
作者：
Boyko, A. N. [1 ]
Gusev, E. I.
机构：
[1] Pirogov Russian Natl Res Med Univ, Moscow, Russia
来源：
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA | 2013年 / 113卷 / 02期
关键词：
multiple sclerosis; therapy; neuroprotection; laquinimod; SECONDARY PROGRESSIVE MS; KAPPA-B; LINOMIDE; ABR-215062; TRIAL;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
New oral therapies of MS cause great attention. This review includes data on the II and III phase clinical studies of laquinimod (LAQ) - a new oral therapy for MS with immunoregulatory, anti inflammatory and neuroprotective action. LAQ has no immunosupressive effects and has a very good safety and tolerability profile. Data of phase III studies including 2437 MS patients confirmed positive effect of LAQ on relapse rate and disability progression. These clinical results were supported by the MRI data, showing also a significant slowing of the brain atrophy. Russian neurological clinics actively participated in all LAQ clinical trials: 241 MS patients from 11 centers from Russia took part in the phase II trials. The data in this subgroup confirm all changes, registered in the whole group of patients.
引用
收藏
页码：93 / 99
页数：7
相关论文
共 50 条
  • [1] Oral laquinimod treatment in multiple sclerosis
    Fernandez, O.
    NEUROLOGIA, 2011, 26 (02): : 111 - 117
  • [2] Evidence for a neuroprotective effect of oral laquinimod in relapsing-remitting multiple sclerosis
    Filippi, M.
    Rocca, M. A.
    De Stefano, N.
    Jeffery, D.
    Kappos, L.
    Montalban, X.
    Boyko, A. N.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 389 - 389
  • [3] Laquinimod, a new oral drug for multiple sclerosis
    Keegan, B. Mark
    Weinshenker, Brian G.
    LANCET, 2008, 371 (9630): : 2059 - 2060
  • [4] Oral laquinimod for multiple sclerosis
    Kelsall, Diane
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2012, 184 (07) : 790 - 790
  • [5] Direct neuroprotective effect of laquinimod on glutamate excitotoxicity in experimental multiple sclerosis
    De Vito, Francesca
    Musella, Alessandra
    Gentile, Antonietta
    Bullitta, Silvia
    Fresegna, Diego
    Mandolesi, Georgia
    Centonze, Diego
    NEUROLOGY, 2017, 88
  • [6] Oral laquinimod for treatment of relapsing-remitting multiple sclerosis
    Weiner, Howard L.
    LANCET NEUROLOGY, 2008, 7 (08): : 672 - 673
  • [7] Profile of oral laquinimod and its potential in the treatment of multiple sclerosis
    West, Matthew S.
    Miravalle, Augusto
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2011, 1 : 25 - 32
  • [8] Oral Laquinimod for Multiple Sclerosis REPLY
    Comi, Giancarlo
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26): : 2527 - 2528
  • [9] Laquinimod in the treatment of multiple sclerosis: a review of the data so far
    Thoene, Jan
    Linker, Ralf A.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1111 - 1118
  • [10] Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis
    Brueck, Wolfgang
    Zamvil, Scott S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (03) : 245 - 256
12345